Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Mariam Hamid

Ophthalmology Detroit, MI Medical Doctor

NPI 1205332335 CMS profile 8800234

2799 W Grand Blvd, Detroit, MI 48202

Open in the dashboard

General payments

$3,017

41 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mariam Hamid of Detroit, MI is reported in the CMS Open Payments database as having received $3,017 across 41 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $150 1
2023 General $32 1
2022 General $527 7
2021 General $2,092 27
2020 General $216 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mariam Hamid
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Mariam Hamid were reported at $150. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Mariam Hamid Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $216 $126 $45–$321 $114
2021 $2,092 $205 $76–$534 $132
2022 $527 $266 $100–$678 $149
2023 $32 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $150 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Bausch & Lomb, a division of Bausch Health US, LLC $1,645 20 payments
  2. Alcon Vision LLC $992 10 payments
  3. Regeneron Healthcare Solutions, Inc. $181 6 payments
  4. Sight Sciences, Inc. $118 1 payment
  5. Allergan Inc. $37 2 payments
  6. TissueTech, Inc. $24 1 payment
  7. Bausch & Lomb Americas Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $1,867 34 payments
  2. Travel and Lodging $1,149 7 payments
Products named General payments · program years 2020–2025
  1. Crystalens Accommodating IOL (AT-52AO) $1,629 19 payments
  2. Akreos AO IOL $1,629 19 payments
  3. Trulign IOL $1,629 19 payments
  4. enVista MX60 IOL $1,629 19 payments
  5. STELLARIS $1,629 19 payments
  6. Centurion $278 3 payments
  7. AcrySof IQ VIVITY $236 2 payments
  8. Clareon $182 2 payments
  9. EYLEA $181 6 payments
  10. AcrySof IQ VIVITY IOL $149 1 payment
  11. Other $385 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,068

Median for Ophthalmology: 891

Drug cost

$47,955

Median for Ophthalmology: $68,233

Branded share of claims

37.9%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 303 $10,328
Cyclosporine Generic 31 $9,855
Restasis Cyclosporine Brand 14 $8,186
Xiidra Lifitegrast Brand 11 $7,540
Moxifloxacin Moxifloxacin Hcl Brand 227 $4,080
Ketorolac Tromethamine Generic 177 $2,562
Erythromycin Erythromycin Base Brand 110 $1,507
Latanoprost Generic 99 $1,271
Brimonidine Tartrate Generic 14 $922
Valacyclovir Valacyclovir Hcl Brand 11 $511

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$46,497

Medicare's payments for the services billed

Medicare patients

173

Average age 74

Services billed

501

119 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 43%
Chronic kidney disease 31%
Ischemic heart disease 22%
Depression 20%
COPD 18%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

41 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record